Skip to main content
NTLA
NASDAQ Life Sciences

Intellia Therapeutics Launches $180M Public Offering at Deep Discount Following Positive Phase 3 Data

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$12.43
Mkt Cap
$1.47B
52W Low
$6.83
52W High
$28.25
52W Position info
82% above low
Off High info
56% below high
Rel. Volume info
5.7× avg
Market data snapshot near publication time

NTLA sits 82% above its 52-week low of $6.83 on elevated volume (5.7× avg).

Summary

Intellia Therapeutics announced a $180 million public offering of common stock at a significant discount, two days after reporting positive Phase 3 clinical trial results for its lead gene-editing therapy, lonvo-z.


Key Events · Financing and Capital Events · NTLA

  • Significant Public Offering Launched

    Intellia Therapeutics is offering 16,744,187 shares of common stock, with underwriters having an option to purchase an additional 2,511,628 shares.

  • Substantial Capital Raise

    The offering is expected to generate approximately $169.2 million in net proceeds for the company, potentially increasing to $194.6 million if the underwriters' option is fully exercised.

  • Deep Discount Pricing

    Shares are priced at $10.75 each, which is a notable discount to the stock's last reported sale price of $15.87 on April 23, 2026, and also below today's market price of $12.43.

  • Strategic Funding Post-Positive Clinical Data

    This capital raise follows the announcement of highly positive topline Phase 3 results for lonvo-z on April 27, 2026, and is intended to fund clinical development, prepare for commercial launch, and for general corporate purposes, extending the cash runway into 2028.


Analysis · NTLA · Life Sciences

Intellia Therapeutics is conducting a substantial public offering of 16.7 million shares, aiming to raise approximately $169.2 million in net proceeds (potentially $194.6 million if underwriters exercise their option). This capital raise, representing a significant portion of the company's market capitalization, is intended to fund the clinical development and commercial launch of its lead programs, including lonvo-z, which just reported highly positive Phase 3 results two days prior. While raising capital is a necessary step for a biotech company transitioning to commercialization, the offering is priced at $10.75 per share, a deep discount compared to the stock's last reported sale price of $15.87 on April 23, 2026, and today's market price of $12.43. This aggressive pricing suggests a strong need for capital and could exert downward pressure on the stock despite the recent clinical success.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NTLA was trading at $12.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $6.83 to $28.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NTLA - Latest Insights

NTLA
Nov 12, 2026, 4:14 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.60
Real-time Price: $9.80 info
Change: -$0.800 (-8%) info
Market Cap: $1.361B info
NTLA
Nov 12, 2026, 10:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $10.72
Real-time Price: $9.80 info
Change: -$0.920 (-9%) info
Market Cap: $1.361B info
NTLA
Nov 05, 2026, 8:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $12.30
Real-time Price: $9.80 info
Change: -$2.50 (-20%) info
Market Cap: $1.361B info
NTLA
Sep 08, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $12.74
Real-time Price: $9.80 info
Change: -$2.94 (-23%) info
Market Cap: $1.361B info
NTLA
Sep 08, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $13.69
Real-time Price: $9.80 info
Change: -$3.89 (-28%) info
Market Cap: $1.361B info